Sanofi and Johnson & Johnson ended development of an experimental vaccine after it failed to adequately protect against an invasive form of the digestive pathogen E. coli. Sanofi recorded a $250 ...
Sanofi (NASDAQ:SNY) said on Thursday that it is discontinuing the late-stage trial for its vaccine to prevent E. coli bacteria infection as it failed to demonstrate sufficient efficacy. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback